AbbVie - Phase 2 Study of Upadacitinib Alone or as a Combina

NORTH CHICAGO - AbbVie today announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active... | June 1, 2023

Related Keywords

Oklahoma , United States , Roopal Thakkar , Kristin Pawliw , Joan Merrill , Exchange Commission , Lupus Erythematosus National Assessment , Arthritis Clinical Immunology Research Program , European Congress , Oklahoma Medical Research Foundation , Flare Index , Lupus Low Disease Activity State , Medical Research Foundation , Clinical Immunology Research , Allergan Aesthetics , Private Securities Litigation Reform Act , Risk Factors , Quarterly Reports , News Publishing , Abbvie Inc Stock Exchange , News , Information , Press Release , North , Chicago , Abbvie , Oday , Nnounced , The , Results , F , Hase , , Leek , Study , Valuating , Upadacitinib , Alone , End , N , Combination , Thigh , Nose , Adults , Ith , Moderately , O , Everely Abbv Us00287y1091 ,